Loading...
•
Dec 31, 2022
Avista Q4 2022 Earnings Report
Reported net income for the fourth quarter of 2022, showing an increase compared to the same period in 2021, and confirmed 2023 earnings guidance.
Key Takeaways
Avista Corp. reported a net income of $78.0 million, or $1.05 per diluted share, for the fourth quarter of 2022, compared to $50.9 million, or $0.71 per diluted share, for the fourth quarter of 2021. The company confirmed its 2023 consolidated earnings guidance with a range of $2.27 to $2.47 per diluted share.
Net income for Q4 2022 was $78.0 million, or $1.05 per diluted share, compared to $50.9 million, or $0.71 per diluted share, for Q4 2021.
Consolidated earnings for 2022 were better than expected due to increases in the fair value of certain non-regulated investments.
Avista Utilities' earnings were slightly below expectations due to higher power supply costs.
The company filed a multi-year rate plan in Idaho to recover infrastructure investment and increased operating costs.
Avista
Avista
Forward Guidance
Avista Corp. is confirming its 2023 consolidated earnings guidance with a range of $2.27 to $2.47 per diluted share.
Positive Outlook
- Timely and appropriate rate relief in all of our jurisdictions
- Avista Utilities to contribute in the range of $2.15 to $2.31 per diluted share.
- Expect to be in the deadband of the ERM, with an increase to earnings of $0.03 per diluted share.
- Expect to manage our operating costs to an increase of 2 percent in 2023.
- AEL&P to contribute in the range of $0.08 to $0.10 per diluted share.
Challenges Ahead
- Unrecovered structural costs estimated to reduce the return on equity by approximately 70 basis points
- Regulatory timing lag estimated to reduce the return on equity by approximately 80 basis points.
- Expected return on equity for Avista Utilities of approximately 7.9 percent in 2023.
- Guidance assumes normal precipitation, temperatures, hydroelectric generation, and other operating conditions.
- Guidance does not include the effect of unusual or non-recurring items until the effects are known and certain.